Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the stocks Jim Cramer recently discussed. Hims & Hers ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Hims & Hers Health (HIMS) is quickly becoming one of the most compelling stories in the market as an emerging powerhouse in the direct-to-consumer healthcare space. The stock has posted outsized gains ...

Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient ...

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...